The Ehlers-Danlos syndromes (EDS) are a group of 14 heritable connective tissue disorders characterized by generalized joint hypermobility, tissue fragility, and multi-organ involvement. 1-3 Despite evidence of familial inheritance, the most common form of EDS, hypermobile EDS (hEDS), lacks a genetically validated cause. The impacts of hEDS can include frequent joint dislocations and subluxations, tendon and ligament laxity, skin hyperextensibility, connective tissue fragility, and chronic pain. Additionally, patients experience various systemic manifestations including comorbidities affecting the gastrointestinal tract, cardiovascular system, and immune system. 2, 3 The combination of variable symptom presentation, limited clinical awareness, and the absence of genetic markers can result in delays of several decades before a diagnosis is made for hEDS patients, leading to worsened health outcomes. 4
To identify genetic causes for hEDS, a genetic registry was developed at the Medical University of South Carolina (MUSC). Within this registry, a four-generation family was identified that presented with autosomal dominant hEDS. Eleven family members were enrolled for genetic analysis, of whom five met the clinical diagnostic criteria for hEDS and three were coded as probable due to age and clinical history at time of analyses (Figure 1A, Figure S1). Whole exome sequencing (WES) of the proband (IV-1) and a second cousin (IV-4) was performed. Following variant filtering (see methods), four rare and potentially damaging variants were shared between the affected individuals (IV-1 and IV-4). PCR amplification and targeted sequencing of all enrolled family members identified only one of these variants with a perfect phenotype-genotype segregation throughout the pedigree (Figure 1A, C). This variant, located in the Kallikrein serine-protease gene KLK15 (chr19:50825890-C-T), was also found in affected members of a second family (Figure 1B, Figure S1). The single nucleotide polymorphism (SNP) results in a missense change (KLK15 p. Gly226Asp), is rare in the population with a minor allele frequency (MAF) of 0.002 (gnomAD v2.1.1), and is predicted to be damaging with CADD and DANN scores of 24 and 0.998, respectively. To determine relevance to connective tissue biology, RT-PCR was performed and confirmed KLK15 mRNA expression in glandular and connective tissues isolated from human and mouse biopsies (Figure 1D, E).
KLK15 is part of a contiguous cluster with 14 other members of the Kallikrein gene family on chromosome 19q13.33 (Figure 1F). Given the known involvement of Kallikreins in regulating one another through activation cascades, and their shared expression patterns in connective tissues (Figure S2, S3), we evaluated the genetic burden of the entire KLK family of genes in a larger hEDS cohort. WES was performed on 197 clinically diagnosed, unrelated hEDS patients and filtered for KLK variants with MAFs less than 0.01 (<1%) in gnomAD. A total of 76 variants were identified, with 48 being unique in the cohort and 65 patients having at least one rare variant in a KLK gene (32.8%) (Figure S4). A gene-based burden test was used to evaluate enrichment of rare variants in individual KLK genes and the entire contiguous gene cluster in hEDS patients (see methods). 5 Significant enrichment for qualifying variants was observed in 11 of the 15 KLK genes with p-value <0.05 as well for the entire KLK gene cluster (considered as whole, p = 2.28×10−14) (Figure 1F, Figure S5); thus supporting a broad role for Kallikrein genes in hEDS.
To provide functional support for the role of Kallikrein in hEDS pathogenesis, CRISPR-Cas9 was used to create knock-in mice with the corresponding familial KLK15 variant (Figure S6). The Achilles tendon, which shows high KLK15 expression in both mice (Figure 1D) and humans (Figure S2, S3), was chosen for analysis. This selection was further justified by reports of Achilles tendon ruptures in members of family 1, making it a relevant tissue to assess for structural and functional deficits in the mice. Freshly isolated Achilles tendons from Klk15G224D/+ (N=8) and control mice (N=9) were subjected to mechanical testing. Microcomputed tomography (mCT) analyses demonstrated Klk15G224D/+tendons were similar in overall anatomical dimensions compared to controls (Figure S7, S8). Stress-strain curves revealed a larger displacement, higher strain, and lower toe modulus in Klk15G224D/+mice, consistent with a more elastic tissue (Figure 2A-E). This extended toe region occurs without significant changes in deformation at endpoints and is consistent with previous studies on ligament injuries. 6, 7 As these mechanical changes are indicative of a structural collagen deficit, ultrastructural analyses were performed on Achilles tendons by transmission electron microscopy (TEM) (Figure 2F-H). Image analyses and quantification of collagen fibrils was performed on a total of 20 independent regions throughout tendons from five Klk15+/+ (N=3,240 fibrils) and 24 independent regions from six Klk15G224D/+(N=4,191 fibrils) mice. An overall 20% reduction in fibril diameter was observed in mutant mice compared to controls with p<0.0001 (Figure 2G). Parsing data into 10nm increments revealed smaller collagen fibrils in Klk15G224D/+ tendons compared to controls (Figure 2H), which correlated with increased elasticity and reduced mechanical strength in Klk15G224D/+tendons. 8
As cardiovascular defects are a relatively common finding within the hEDS population, hearts from Klk15G224D/+(N=6) and Klk15+/+ (N=5) mice were analyzed using echocardiography and histopathology. Although overall cardiac function was normal (Figure S9), valve dysfunction was observed in 83% (5/6) of the mutant mice, with 80% (4/5) having demonstrable prolapse of the mitral leaflets (Figure 2I). None of the control animals had detectable defects in valve function. Myxomatous degeneration of mitral and aortic valves, as assayed by Movat’s Pentachrome stain, was evident in 75% (3/4) of mutant mice compared to 0% (4/4) of controls (Figure 2J). Given previous reports on hEDS patients having an increased risk for changes in aortic dimensions 9, we examined whether this was apparent in the Klk15G224D/+hEDS mouse model. Consistent with these prior reports, Klk15G224D/+had slightly enlarged aortic dimensions, trending toward significance (p=0.0532) (Figure 2K, S10).
This study provides the first genetic and biological evidence for the involvement of Kallikrein gene variants in hEDS. Through WES of two families, we identified the KLK15 p.G226D variant. Supporting this genetic discovery, in vivo data demonstrated that the KLK15 variant causes structural and functional effects across multiple organ systems in a murine model, consistent with an hEDS phenotype. In a cohort of 197 hEDS patients, we observed enrichment of Kallikrein variants, with 32.8% of patients harboring at least one KLK variant. While most Kallikrein variants identified are exceedingly rare, the familial KLK15 variant has a slightly higher MAF. Similar studies have identified causative dominant missense variants with MAFs between 0.0001 and 0.005 in complex Mendelian diseases. 10-13 Factors such as genetic background, environmental exposures, potential under-diagnosis, incomplete penetrance, and reduced expression likely contribute to the genotype-phenotype correlation in hEDS.
Exploring the molecular consequences of Kallikrein variants will not only uncover mechanisms of normal connective tissue development and disease but also shed light on the comorbidities commonly associated with hEDS. Notably, Kallikreins are known to interact with substrates in the extracellular matrix, influencing the connective tissue environment in both homeostasis and disease.14 This class of genes also plays roles in blood pressure regulation and immune cell function, potentially contributing to various comorbidities such as postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome, which are frequently observed in hEDS patients. 15 Relatedly, it is curious that there is a tight interaction between Kallikrein’s and in the innate immune system, specifically the complement system. Kallikreins can cleave complement 3 (C3) and 5 (C5) directly, leading to the generation of C3a and C5a16, which are potent anaphylatoxins that enhance inflammation upstream of mast cell activation. Additionally, in certain pathological conditions such as hereditary angioedema (HAE), dysregulation of the interlinked kallikrein system and the complement pathway can lead to excessive inflammation and tissue swelling17, features observed in hEDS patients.
Given the autosomal dominant mode of inheritance and the variability of phenotypes associated with hEDS, it is likely that KLK gene variants, such as KLK15G226D, function primarily in a dominant-negative manner. However, given the known synergistic hierarchy of Kallikreins, where they auto-activate and catalyze the activation of downstream Kallikrein enzymes, even subtle changes in expression levels due to loss-of-function alleles may have damaging effects. While we implicate KLK variants in hEDS, they represent just one aspect of the genetic landscape. The absence of damaging Kallikrein variants should not preclude patients from receiving a clinical diagnosis of hEDS. Although our study indicates the likelihood of additional families and sporadic individuals harboring rare monogenic causes, genome-wide approaches hold promise for revealing the complex genetic architecture of hEDS.
Hypermobile Ehlers-Danlos Syndrome is a connective tissue disorder that impacts many tissues and organ systems. Management of symptoms is challenging and often requires an interdisciplinary team of well-informed clinicians who understand the complexities of hEDS. Studies focusing on the pathophysiology of hEDS are in their infancy, underscoring the need for better clinical understanding. Elucidation of genetic causes and biological pathways involved in hEDS is critical for earlier diagnoses, which can reduce the healthcare burden and improve quality of life. This report provides a first critical step toward mechanistic understanding of disease pathogenesis, paving the way for improved diagnostic tools and enhanced prognoses for patients with hypermobile Ehlers-Danlos Syndrome.